Elisa De Carlo

Centro di Riferimento Oncologico

Emailelisa.decarlo@cro.it

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Elisa De Carlo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

73 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

11 Article

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
study, CLARITY., Bersanelli, M., Buti, S., Giannarelli, D., Leonetti, A., Cortellini, A., Russo, G. L., Signorelli, D., Toschi, L., Milella, M., Pilotto, S., Bria, E., Proto, C., Marinello, A., Randon, G., Rossi, S., Vita, E., Sartori, G., D'Argento, E., Qako, E. & 31 others, Giaiacopi, E., Ghilardi, L., Bettini, A. C., Rapacchi, E., Mazzoni, F., Lavacchi, D., Scotti, V., Ciccone, L. P., De Tursi, M., Di Marino, P., Santini, D., Russano, M., Bordi, P., Di Maio, M., Audisio, M., Filetti, M., Giusti, R., Berardi, R., Fiordoliva, I., Cerea, G., Pizzutilo, E. G., Bearz, A., De Carlo, E., Cecere, F., Renna, D., Camisa, R., Caruso, G., Ficorella, C., Banna, G. L., Cortinovis, D. & Garassino, M. C., Dec 2020, In: Lung Cancer. 150, p. 123-131 9 p.
Research output: Contribution to journal › Article › peer-review
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
CLARITY study, Dec 2020, In: Lung Cancer. 150, p. 123-131 9 p.
Research output: Contribution to journal › Article › peer-review
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
CLARITY study, Dec 2020, In: Lung Cancer. 150, p. 123-131 9 p.
Research output: Contribution to journal › Article › peer-review
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
Bersanelli, M., Buti, S., Giannarelli, D., Leonetti, A., Cortellini, A., Russo, G. L., Signorelli, D., Toschi, L., Milella, M., Pilotto, S., Bria, E., Proto, C., Marinello, A., Randon, G., Rossi, S., Vita, E., Sartori, G., D'Argento, E., Qako, E., Giaiacopi, E. & 32 others, Ghilardi, L., Bettini, A. C., Rapacchi, E., Mazzoni, F., Lavacchi, D., Scotti, V., Ciccone, L. P., De Tursi, M., Di Marino, P., Santini, D., Russano, M., Bordi, P., Di Maio, M., Audisio, M., Filetti, M., Giusti, R., Berardi, R., Fiordoliva, I., Cerea, G., Pizzutilo, E. G., Bearz, A., De Carlo, E., Cecere, F., Renna, D., Camisa, R., Caruso, G., Ficorella, C., Banna, G. L., Cortinovis, D., Brighenti, M., Garassino, M. C. & Tiseo, M., Dec 1 2020, In: Lung Cancer.
Research output: Contribution to journal › Article › peer-review
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
Facchinetti, F., Mazzaschi, G., Barbieri, F., Passiglia, F., Mazzoni, F., Berardi, R., Proto, C., Cecere, F. L., Pilotto, S., Scotti, V., Rossi, S., Del Conte, A., Vita, E., Bennati, C., Ardizzoni, A., Cerea, G., Migliorino, M. R., Sala, E., Camerini, A., Bearz, A. & 21 others, De Carlo, E., Zanelli, F., Guaitoli, G., Garassino, M. C., Ciccone, L. P., Sartori, G., Toschi, L., Dall'Olio, F. G., Landi, L., Pizzutilo, E. G., Bartoli, G., Baldessari, C., Novello, S., Bria, E., Cortinovis, D. L., Rossi, G., Rossi, A., Banna, G. L., Camisa, R., Di Maio, M. & Tiseo, M., 2020, In: Eur. J. Cancer. 130, p. 155-167 13 p.
Research output: Contribution to journal › Article › peer-review

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status